Nxera pharma notes positive phase 2 data for partnered schizophrenia candidate nbi-1117568

Tokyo, japan and cambridge, uk, 28 august 2024 – nxera pharma co., ltd. (“nxera” or “the company”; tse 4565) – formerly known as sosei group or sosei heptares – notes the announcement by its partner neurocrine biosciences inc. (“neurocrine”; nasdaq: nbix) that nbi-1117568 (nbi-‘568) has delivered positive topline results from its phase 2 clinical study in adults with schizophrenia. nbi-'568 is the first investigational, oral, muscarinic m4 selective agonist in development for the treatment of schizophrenia.
NBIX Ratings Summary
NBIX Quant Ranking